The Orthobiologics Market Size was valued at USD 7.5 billion in 2022 and is projected to grow from USD 8.04 Billion in 2023 to USD 14.02 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.2% during the forecast period (2023 - 2032). The increase in the rate of sports injuries across the globe, the continuous influx of new products and treatment options, technological advancements in synthetic biology, and the rise in demand for minimally invasive surgeries are the key market drivers boosting the orthobiologics market growth.
Source Secondary Research, Primary Research, MRFR Database, and Analyst Review
The prevalence of orthopedic disorders has increased ly over the past ten years. Poor eating habits and insufficient exercise can negatively impact the body's homeostasis. This problem worsens with age, making most people in the 60+ age range more susceptible to orthopedic conditions like arthritis. People in this age range with osteoarthritis may experience joint pain and stress on their lower back, hips, and knees. The population of this age group has increased further due to more advanced treatment options and better healthcare standards that have increased life expectancy.
For instance, more than 6.8 million patients in the United States seek medical care each year due to orthopedic injuries, according to statistics from the American Academy of Orthopedic Surgeons. This sizable patient base that needs to be treated for orthopedic injuries could accelerate market growth in the upcoming years. The CDC estimates that in 2023, 65.6% of adults 65 and older will seek the services of a dental surgeon. The need for orthobiologics to treat or bind joint disorders has increased due to the prevalence of orthopedic issues. As a result, the growing number of orthopedic conditions will increase demand for orthobiologics, driving the orthobiologics market revenue growth.
Orthobiologics therapy focuses on repairing damaged tissues by utilizing the body's regenerating and healing capabilities. Platelet-rich plasma (PRP), autologous chondrocyte implantation (ACI), bone marrow concentrate (BMC), adipose tissue-derived mesenchymal stem cells (ADMSC), and autologous conditioned serum are some of the innovative orthobiologics options that can help treat osteoarthritis. The accessibility of such products has resulted in the avoidance of operative procedures like knee arthroplasty for osteoarthritis treatment. This, in turn, is anticipated to boost the growth of the orthobiologics market CAGR throughout the forecast period.
Based on product, the orthobiologics market segmentation includes a demineralized bone matrix and bone morphogenetic protein. The bone morphogenetic protein segment held the majority share in 2022, contributing around ~65-67% to the orthobiologics market revenue. This factor is mainly due to the rise in degenerative arthritis and osteoarthritis of the knee, especially in the aging population. Improvements in reimbursement policies for bone morphogenetic protein supplements assist the segment's growth. Other factors supporting the segment's highest share include recent orthobiologics market product approvals and the entry of new manufacturers.
January 2021 QuickPack, an utterly synthetic alternative to a bone graft, was introduced in the United States by OrthoPediatrics Corp. The product is made of high-viscosity calcium and phosphate cement that closely resembles the mineral phase of bone cells.
Based on application, the orthobiologics market segmentation includes osteoarthritis & degenerative arthritis and spinal fusion. The spinal fusion segment led the market in 2022 and is projected to be the faster-growing segment during the forecast period 2022-2030. The advantages of orthobiological products in spinal fusion, including rapid stimulation of cells to initiate bone formation, shorter hospital stays, and fewer hospital visits, are considered responsible for growing a larger share of the application segment. Additional factors contributing to the segment's high market share include the rising frequency of spinal fusion operations worldwide. Moreover, critical companies with a diverse product portfolio of orthobiologics products for the spinal fusion application area and rising approvals for new products for spinal fusion procedures are expected to drive segment market growth in the coming years.
May 2021 Prosidyan received CE mark accreditations for its fibergaft bone graft replacements for spinal fusion procedures in the orthobiologics industry.
The orthobiologics market data has been bifurcated by end users into hospitals and orthopedic clinics. The hospital segment dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period 2022-2030. The primary factor driving the most significant shares of this market is the growing use of orthobiological products in various spinal and reconstructive surgeries carried out in hospitals. An increase in hospitals in developed and developing nations and a rise in spinal disorders and bone joint complications frequency also fuels segmental growth. The development of this market is attributed to factors like specialized patient care and the accessibility of a wide variety of orthobiologics in hospitals. A further factor in the segment's growth is the supportive infrastructure, which makes precise operational procedures possible.
Figure 2 Orthobiologics Market, by End User, 2022 & 2030 (USD Billion)
Source Secondary Research, Primary Research, MRFR Database, and Analyst Review
Further, the orthopedic clinic's segment is expected to grow at a lucrative CAGR in the orthobiologics industry from 2022 to 2030. The growing demand for orthopedic specialty care, combined with an increase in the number of specialty clinics across developed markets for efficient management and treatment of bone defects, is expected to drive the segment's fastest growth.
By Region, the study provides market insights into Europe, North America, Asia-Pacific, and the Rest of the World. The North American orthobiologics market accounted for USD 3.43 billion in 2022 and is expected to exhibit a significant CAGR growth during the study period. This region's orthobiologics market share is due to many key players promoting quality care and developing new product development strategies. Besides, reimbursement for soft tissue healing and fusion enhancement products significantly contributes to the regional share. Moreover, North America's large patient population pool is expected to contribute to market growth by requiring orthobiologics products to fill bone voids and other bone defects.
Further, the major countries studied in the market report are the U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 3 ORTHOBIOLOGICS MARKET SHARE BY REGION 2022 (%)
Source Secondary Research, Primary Research, MRFR Database, and Analyst Review
The European orthobiologics market accounts for the second-largest market share. The intense focus of European market players on R&D expenditures and research activities, favorable health reimbursement for bone grafting processes, and the rapidly increasing incidence of spinal injuries are expected to drive orthobiologics demand in the coming years. Further, the German orthobiologics market held the largest market share, and the UK orthobiologics market was the fastest-growing market in the European region.
The Asia-Pacific Orthobiologics Market is anticipated to grow at the fastest CAGR from 2022 to 2030. The growth of the orthobiologics market in the Asia Pacific region can be attributed primarily to rising healthcare spending, rising disposable income, and increased physician awareness of the advantages of these products. As the Asia Pacific region develops, there are opportunities for key players to invest. The orthobiologics market is growing incredibly in this region, in addition to improving the quality of the healthcare infrastructure. Aside from the increased product launches in this region, there is increasing competition among the key players, contributing significantly to the Asia Pacific's leading growth of the orthobiologics industry. Moreover, China’s orthobiologics market held the largest market share, and the Indian orthobiologics market was the fastest-growing market in the Asia-Pacific region.
Orthobiologics Key Market Players & Competitive Insights
The orthobiologics market is highly consolidated, with a small number of dominant players. Major market players are focusing on developing antibiotic-eluting bone void injectables to treat bone diseases, which will drive the overall growth of the orthobiologics industry. Vendors are enhancing their market presence through key market development strategies such as strategic alliances, collaborations, geographical expansion, mergers and acquisitions, regulatory approvals, and new product/service launches.
In recent years, the orthobiologics industry has delivered some of the most substantial benefits to regenerative medicine. The orthobiologics market major players, such as Integra LifeSciences, Arthrex Inc, Stryker Corporation, Globus Medical Inc, and others, are working on expanding the market demand by heavily investing in research and development activities. Competing companies in the orthobiologics industry must provide affordable products to grow and survive in a market that is becoming more and more competitive.
ChitogenX Inc (formerly Ortho Regenerative Technologies Inc) is a clinical-stage regenerative medicine firm focused on developing novel therapeutic tissue repair technologies to improve tissue healing. The company has announced that in May 2022, the US Patent and Trademark Office issued a patent related to the company's ORTHO-R soft tissue repair platform. The Freeze-Dried Polymer Compositions patent allows for mixing freeze-dried polymer compositions with platelet-rich plasma to form implants for tissue repair and compositions for therapeutic intra-articular injection. It safeguards Ortho R Technology's composition and application process.
Biocomposites is a multinational medical device firm that develops, manufactures, and markets cutting-edge product lines for infection management in soft tissue and bone. Biocomposites is a leader in developing novel calcium compounds for surgical applications. Its products address various infection risks in multiple specialties, such as musculoskeletal infection, orthopedics, trauma, spine, foot, ankle, and podiatry. In April 2020, Biocomposites announced that its STIMULAN product offering had received a new CE Mark authorization to incorporate antibiotics, such as tobramycin, vancomycin, and gentamicin in periosteum void fillers, that can be utilized as a treatment option in the management of parasitized bone and soft tissues.
Key Companies in the orthobiologics market include
Orthobiologics Industry Developments
March 2022 MTF Biologics formed a collaboration with Bone Biologics Corporation. The partnership aimed to distribute Demineralized Bone Matrix (DBM) from Bone Biologics Corporation in the orthobiologics market.
June 2021 Bioventus Inc has announced the availability of the SIGNAFUSE bone graft in a new strip layout for orthobiologics solutions.
July 2020 Spine Wave announced the successful launch of Tempest Allograft Bone Matrix on the market and its entry into the spinal biologics industry.
October 2020 Orthofix Medical Inc has introduced the O-Genesis graft delivery mechanism and the AlloQuent compositional allograft Q-Pack.
| Report Attribute/Metric | Details |
| Market Size 2022 | USD 7.5 billion |
| Market Size 2023 | USD 8.04 billion |
| Market Size 2032 | USD 14.02 billion |
| Compound Annual Growth Rate (CAGR) | 7.2% (2023-2032) |
| Base Year | 2022 |
| Market Forecast Period | 2023-2032 |
| Historical Data | 2018 - 2021 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Product, Application, End User, and Region |
| Geographies Covered | Europe, North America, Asia Pacific, and the Rest of the World |
| Countries Covered | The U.S., Germany, Canada, U.K., Italy, France, Spain, Japan, China, Australia, India, South Korea, and Brazil |
| Key Companies Profiled | Exactech Inc, Arthrex Inc, Integra LifeSciences, Globus Medical Inc, Johnson & Johnson, NuVasive Inc, Stryker Corporation, Medline Industries Inc, Wright Medical Group N.V., Zimmer Biomet |
| Key Market Opportunities | Growing demands for effective trauma healing agents for muscular and sports injuries |
| Key Market Dynamics | Increased demand for non-surgical osteoarthritis treatments Increase in the number of spinal and sports-related injuries worldwide |
Orthobiologics Market Highlights:
Frequently Asked Questions (FAQ) :
Orthobiologics market is expected to reach USD 14.02 billion by 2032.
The orthobiologics market size was valued at USD 7.5 Billion in 2022.
The market is projected to grow at a CAGR of 7.2% during the forecast period, 2023-2032.
North America had the largest revenue share of the market.
The key players in the market are Exactech Inc, Arthrex Inc, Integra LifeSciences, Globus Medical Inc, Johnson & Johnson, NuVasive Inc, Stryker Corporation, Medline Industries Inc, Wright Medical Group N.V., Zimmer Biomet.
The bone morphogenetic protein category dominated the market in 2022.
Spinal fusion had the largest revenue share of the market.
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
